Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates
BOOST-CA
1 other identifier
observational
89
1 country
1
Brief Summary
Comparative retrospective study of two anal canal brachytherapy techniques aimed at boosting \[low dose rate (LDR) and high dose rate (HDR)\]
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2007
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 17, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 28, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 28, 2016
CompletedFirst Submitted
Initial submission to the registry
March 5, 2018
CompletedFirst Posted
Study publicly available on registry
March 14, 2018
CompletedMarch 14, 2018
March 1, 2018
9 years
March 5, 2018
March 13, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Evaluation of the efficacy of interstitial brachytherapy of the anal canal
Efficacy of anal canal interstitial brachytherapy evaluated by local relapse rate
1 year
Evaluation of the tolerance of interstitial brachytherapy of the anal canal
Tolerance of interstitial brachytherapy of the anal canal evaluated by the rate of chronic toxicities.
1 year
Secondary Outcomes (4)
Estimation of local control
1 year
Estimation of disease free survival
1 year
Estimation of overall survival
1 year
Comparison of the incidence of toxicities (CTCAE v4) between the 2 groups
1 year
Study Arms (2)
Low Dose Rate
Patients treated with brachytherapy at low dose rate of the anal canal with aim of boost
High Dose Rate
Patients treated by brachytherapy with a high dose rate of the anal canal aiming for boost
Interventions
Eligibility Criteria
Patients treated with anal canal brachytherapy for boost, between 2008 and 2016.
You may qualify if:
- Patients treated by brachytherapy anal canal to boost.
You may not qualify if:
- Patients below age of 18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institut Paoli Calmettes
Marseille, Bouches Du Rhone, 13009, France
Related Publications (2)
Cordoba A, Escande A, Leroy T, Mirabel X, Coche-Dequeant B, Lartigau E. Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers. Brachytherapy. 2017 Jan-Feb;16(1):230-235. doi: 10.1016/j.brachy.2016.07.007. Epub 2016 Sep 3.
PMID: 27600606RESULTBoukhelif W, Ferri-Molina M, Mazeron R, Maroun P, Duhamel-Oberlander AS, Dumas I, Martinetti F, Guemnie-Tafo A, Chargari C, Haie-Meder C. Interstitial pulsed-dose-rate brachytherapy for the treatment of squamous cell anal carcinoma: A retrospective single institution analysis. Brachytherapy. 2015 Jul-Aug;14(4):549-53. doi: 10.1016/j.brachy.2015.03.006. Epub 2015 Apr 29.
PMID: 25935731RESULT
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Leonel VARELA GAGETTI
Institut Paoli-Calmettes
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 5, 2018
First Posted
March 14, 2018
Study Start
August 17, 2007
Primary Completion
July 28, 2016
Study Completion
July 28, 2016
Last Updated
March 14, 2018
Record last verified: 2018-03
Data Sharing
- IPD Sharing
- Will not share